Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos.
Popular Articles

AMA Outlines Initiatives To White House To Help Slow Increases In Health Spending
Statement attributable to: Nancy H. Nielsen, M.D.
pharmacy online
Editorials Examine Sotomayor Confirmation Hearings, Prospects
Four newspapers recently published editorials responding to last week"s confirmation hearings for Supreme Court nominee Sonia Sotomayor. Summaries appear below.~ Boston Globe: Sotomayor "far surpassed" the "meager standard" of "just [having] to avoid saying anything damaging," according to a Globe editorial. During the hearings, she "made it clear she believes that Supreme Court justices base their decisions on the Constitution, the law and the relevant precedents," and her "judicial record offers no reason to think otherwise," the editorial states. It continues that "the hearings did nothing to undermine -- and much to underscore -- the notion that Sotomayor has the right temperament, intellect and credentials for the Supreme Court. She should be confirmed" (Boston Globe, 7/20).~ New York Times: The Senate "has learned more than enough about [Sotomayor"s] qualifications to give her a seat on the court," according to a Times editorial. However, "[i]t would also be good if senators -- and the nation -- had a deeper sense of her views on some of the most pressing legal questions of our times," the editorial continues. It adds, "We were disappointed that at her confirmation hearings last week, she continued what is becoming an unbreakable habit of nominees dodging controversy." For example, "[w]e would have liked to hear her boldly defend the idea of the Constitution as a living document, one that changes with the times," and "we would have preferred if she had used the hearings to explain to the public that the much-mentioned distinction between judges making and applying the law has little meaning," the editorial states. Sotomayor "avoided saying much of substance about abortion rights, the scope of presidential power, and other hot-button issues," although this is "not entirely her fault," as the "Senate has shown repeatedly that it will tolerate this sort of evasion." However, "the public has a right to know where judicial nominees stand on important legal issues that will have a direct impact on their lives," the editorial states. It concludes, "We hope the Senate confirms her without delay so we can see more clearly what her contribution will be" (New York Times, 7/21).~ Washington Post: During her confirmation hearings, Sotomayor "proved herself well-qualified and worthy of confirmation," according to a Post editorial. The editorial continues, "She spoke convincingly about her belief in and record of consistently respecting legislative prerogatives -- an approach that signals a modest style of judging." Although the hearings focused on Sotomayor defending her previous speeches and comments, her "attempts to explain away and distance herself" from the statement that a wise Latina might make a better decision than a white man "were unconvincing and at times uncomfortably close to disingenuous, especially when she argued that her reason for raising questions about gender or race was to warn against injecting personal biases into the judicial process." The editorial adds, "Her repeated and lengthy speeches on the matter do not support that interpretation." According to the Post, "It"s too bad that she felt she had to disavow her true intent, because, though a wise Latina won"t necessarily judge better than a white man would, diversity on the bench is indeed important" (Washington Post, 7/19).~ Washington Times: During the hearings, Republican senators "failed to ask questions of great relevance to public understanding of the judge"s record and integrity," a Times editorial states. The editorial continues, "They owe it to all Americans to get tough enough to force an examination of whether the judge may have perjured herself during her testimony." According to the editorial, "The questions for which Judge Sotomayor"s answers are almost impossible to believe involved legal briefs on abortion cases that were filed by the Puerto Rican Legal Defense and Education Fund during the 12 years Judge Sotomayor sat on its board." Republican senators also "failed to ask sharp f
News of the day
Mammograms Not Improved By A Break From Hormone Therapy
Some women take a short break from using postmenopausal hormone therapy before getting their breasts screened for cancer with mammography. They hope to lower their risk of being called back afterward for unnecessary extra breast imaging. But taking a short break from hormones doesn"t actually work for this purpose, according to the first large-scale randomized controlled trial to address the question. The READ (Radiological Evaluation and Breast Density) trial of more than 1,700 Group Health women is in the June 2, 2009 Annals of Internal Medicine.
Medical Devices

FDA Grants LUCAS™ 2 Chest Compression System 510(k) Clearance In The United States

Physio-Control Inc., a wholly-owned subsidiary of Medtronic, Inc. (NYSE: MDT), announced today that LUCAS™ 2, the next-generation LUCAS™ Chest Compression System, has been granted 510(k) market clearance by the U.S. Food and Drug Administration (FDA). Developed and manufactured by Jolife AB and distributed exclusively in the United States by Physio-Control, the LUCAS 2 is an automated, battery-powered device that is designed to give consistent, uninterrupted compressions to victims in cardiac arrest. Since performing manual chest compressions according to the American Heart Association guidelines is both difficult and physically demanding, Jolife created the LUCAS Chest Compression System to assist. LUCAS is designed to deliver uninterrupted compressions at a consistent rate and depth (100 compressions per minute, depth 1.5 to 2 inches) to facilitate the return of spontaneous circulation in cardiac arrest patients. By ensuring consistent blood flow, LUCAS helps emergency medical responders deliver a more viable candidate for recovery to the Emergency Department. Furthermore, LUCAS can assist in improving the operations of an emergency response system or hospital by helping to reduce the chaos on the scene and free up staff for other emergencies. LUCAS 2 builds upon the well-proven LUCAS™ 1 technology, but differs from its predecessor in that it is an electric rather than a pneumatic device. LUCAS 2 can be powered either by battery alone or using a wall or car electricity outlet. The battery is the latest in rechargeable, Lithium Ion Polymer technology and operates for up to 45 minutes (typical) on a single battery. LUCAS 2 is equipped with Smart Restart functionality. When a battery needs to be replaced, LUCAS 2 does not have to be powered down, only put into the pause mode, and when the new battery is inserted, the start position will stay the same within 60 seconds from the pause. Operation can be quickly resumed, saving time for medical personnel. LUCAS 2 offers other new features such as alerts and pauses to aid ventilation during compressions with an unsecured airway (e.g. bag-valve-mask) and quieter operation. "With the LUCAS 2 we now offer a solution to customers that prefer a battery-powered device, and the LUCAS 1 for those who prefer the pneumatic solution," said Erik von Schenck, CEO of Jolife AB. "The rechargeable battery requires a minimum of maintenance, and makes the device the most compact, lightweight and portable mechanical chest compression device on the market." LUCAS 2 weighs only 17.2 lbs (7.8kg) and fits into a compact backpack measuring just 25.6h x 13w x 19.8d inches (65h x 33w x 25d centimeters). "We are proud that our strong partnership with Jolife has enabled us to bring another high-quality, innovative, life-saving product to the emergency care market," said Brian Webster, president of Physio-Control. "Customers have been asking us for a battery-powered LUCAS device for a couple of years and with LUCAS 2 we are able to deliver." Within the past month, LUCAS 2 has also received a CE (Conformitç© Europç©enne) Mark in Europe and marketing approval from Health Canada. Physio-Control plans to begin shipping to the U.S. markets in the fall. About LUCAS CPR LUCAS Chest Compression System is an easy-to-use and lightweight device that provides quality chest compressions according to the European Resuscitation Council and American Heart Association Guidelines for CPR (cardiopulmonary resuscitation). It assists rescuers in facilitating the delivery of vital oxygen to the brain and priming the heart for a defibrillation shock in cardiac arrest situations. LUCAS is simple to use, applied within seconds and feasible for use on most cardiac arrest patients. LUCAS is used by firefighters and paramedics on the scene of a cardiac arrest and used by clinical personnel in the emergency departments and cath labs of hospitals. About Jolife AB Jolife AB, founded in 2000, develops and manufactures the LUCAS Chest Compression System. Jolife works closely with leading physicians and paramedics and is committed to research and development in order to continue to offer innovative products. The LUCAS Chest Compression Systems are sold in the major markets in the world. Based in Lund in southern Sweden, Jolife markets its products through an exclusive global distribution agreement with Physio-Control, Inc., a division of Medtronic, Inc. - except in Sweden, Norway and Finland, where Jolife sells direct. About Physio-Control Physio-Control, a wholly-owned subsidiary of Medtronic, is located in Redmond, Wash. Physio-Control pioneered defibrillation technology more than 54 years ago. With nearly 800,000 LIFEPAK® defibrillators distributed worldwide, the company is the world"s leading provider of external defibrillation and monitoring technology for the treatment of sudden cardiac arrest and other cardio-respiratory emergencies. To find out more about Physio-Control, go to http://www.physio-control.com or call 1-800-442-1142. Medtronic


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009